How to Manage Venetoclax Resistance in Chronic Lymphocytic Leukemia
Experts outline treatment options for patients with venetoclax resistance.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
New Tablet Formulation of Calquence Approved for CLL, SLL, MCL
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules.
Third Dose of COVID-19 Vaccine Appears Least Effective for Lymphoma Patients
Vaccine effectiveness against breakthrough SARS-CoV-2 infections was 10.5% for patients with lymphoma.
Zanubrutinib Bests Bendamustine-Rituximab in Previously Untreated CLL/SLL
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
Usefulness of Bone Marrow Biopsy in Follicular Lymphoma Clinical Trials Questioned
Researchers investigated a hypothesis that posttreatment bone marrow biopsy may not be needed after confirming complete response on imaging in patients with follicular lymphoma.
Zandelisib Displays “Exemplary” Efficacy in Relapsed/Refractory Follicular Lymphoma
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Targeted Radiotherapy Remains Important in Pediatric Hodgkin Lymphoma With Slow Early Response to Chemotherapy
Researchers sought to assess the importance of radiotherapy in pediatric patients with early‐stage low-risk classical Hodgkin lymphoma.
Mosunetuzumab Demonstrates Activity in Relapsed/Refractory Follicular Lymphoma
Mosunetuzumab produced an objective response rate of 80%.
Response-Adapted Nivolumab Salvage Therapy Safe and Effective in Classical Hodgkin Lymphoma
Researchers sought to determine whether response-adapted sequential salvage therapy would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Low Adoption of SC-RT for Lymphoma Among Medicare Beneficiaries
Researchers sought to determine the trends in the utilization of Medicare on short-course radiotherapy in patients with lymphoma.
Tisagenlecleucel Demonstrates Activity in Young Patients With R/R Non-Hodgkin Lymphoma
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
Pola-R-CHP May Be Cost Effective, Depending on PFS Outcomes in Previously Untreated DLBCL
Researchers sought to determine whether the combination pola-R-CHP would be cost-effective for treating patients with previously untreated DLBCL.
Real-World Treatment Outcomes, Roles of Transplantation and Maintenance Rituximab in Mantle Cell Lymphoma
Researchers sought to determine the role and utilization of ASCT in younger patients with MCL.
Generic Equivalent to Istodax Now Available
Romidepsin is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma.
Predicting Disease Progression in Patients With MALT Lymphoma
The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.
Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
Orelabrutinib-Sintilimab Yields Responses in Primary CNS Lymphoma
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
Bortezomib Provides No Benefit Over R-DHAP Alone in R/R DBLCL
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
BEACOPP May Reduce Fertility in Male Survivors of Hodgkin Lymphoma
Male survivors of classical Hodgkin lymphoma had lower childbearing rates if they received BEACOPP rather than ABVD.
Long-Term Efficacy of Zanubrutinib Confirmed for Mantle Cell Lymphoma
The safety profile remained similar to earlier analyses, with the most common grade 3 or higher adverse events including neutropenia and pneumonia.
Response to Axicabtagene Ciloleucel Superior to Standard Care in R/R Large B-Cell Lymphoma
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Pembrolizumab May Improve Responses to Consolidation in Pediatric Classic Hodgkin Lymphoma
Researchers sought to determine whether adding pembrolizumab to consolidation chemotherapy would be effective in pediatric patients with high-risk classic Hodgkin lymphoma.
Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
DA-EPOCH-R No More Effective Than R-CODOX-M/R-IVAC in Burkitt Lymphoma
The 2 regimens produced similar efficacy outcomes, but adverse events were more common in the R-CODOX-M/R-IVAC arm.
Modest Efficacy Seen With Tislelizumab in T-Cell and NK-Cell Lymphomas
Researchers sought to determine whether tislelizumab would be an effective treatment for patients with relapsed/refractory mature T/NK-cell lymphomas.
Zanubrutinib May Improve Response Rate Compared With Ibrutinib in Waldenström Macroglobulinemia
Researchers sough to determine whether zanubrutinib would improve responses compared with ibrutinib in patients with Waldenström macroglobulinemia.
Rituximab Plus Axi-Cel Induced High Response Rates in Large B-Cell Lymphoma
Researchers sought to determine whether adding rituximab to axicabtagene ciloleucel would have efficacy in patients with refractory large B-cell lymphoma.
MicroRNAs in CSF May Help Detect CNS Involvement in B-NHL
Researchers sought to determine whether evaluating circulating microRNAs in cerebrospinal fluid would be a sensitive approach for detecting secondary CNS involvement in B-NHL
Ibrutinib Improves Standard Care in Older Patients With Mantle Cell Lymphoma
Adding ibrutinib to standard chemoimmunotherapy improved the median progression-free survival by 2.3 years.
Features of Fever of Unknown Origin Later Diagnosed as Lymphoma
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
FDA Withdraws Approval of Ukoniq Over Safety Concerns
Updated findings from the UNITY-CLL trial continue to show a possible increased risk of death among patients who received Ukoniq.
Kymriah Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
Risk of Cardiotoxicity With Doxorubicin for DLBCL Does Not Include Ischemic Heart Disease, Stroke
A study compared patients with diffuse large B-cell lymphoma with a 1:10 cohort from the general population to determine the risk of cardiovascular events in patients receiving doxorubicin-containing regimens.
GALEN Combination Yields Promising Results in Untreated Follicular Lymphoma
Researchers sought to determine whether the GALEN regimen would yield favorable clinical outcomes in patients with previously untreated follicular lymphoma.
Tisagenlecleucel Shows Promise in Patients With Primary CNS Lymphoma
Researchers sought to determine whether tisagenlecleucel would be safe and effective in patients with primary central nervous system lymphoma.
Lisocabtagene Maraleucel Associated With Manageable Toxicities, Deep Responses in Relapsed/Refractory CLL or SLL
Researchers sought to determine whether liso-cel would have acceptable toxicity and effectiveness in patients with SLL or CLL.
Lymphoma Treatment Associated With Impaired Response to COVID-19 Vaccination
Researchers sought to determine whether patients with lymphoma receiving anticancer therapy had responses to COVID-19 vaccination.
Results Support Allo-HSCT After CAR-T Failure in Large B-Cell Lymphoma
The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.
Vaccine-Induced Responses to Omicron, Delta Impaired in Non-Hodgkin Lymphoma Patients
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
CAR-T Cell Therapy Fast Tracked for B-Cell Non-Hodgkin Lymphoma
A phase 1 trial is currently evaluating the safety and tolerability of ADI-001 in 76 participants with B cell malignancies.
Ukoniq Taken Off the Market; Pending Applications for CLL, SLL Withdrawn
The decision to withdraw the pending applications was based on an intial review of data from the phase 3 UNITY-CLL trial.
Frontline Consolidation Treatment With ASCT Improved PFS, OS in Peripheral T-Cell Lymphoma
The 5-year progression-free survival rate was significantly better in patients who underwent ASCT compared with those who did not.
Optimal Dosing Combination of Ibrutinib and Venetoclax Identified in Relapsed/Refractory Mantle Cell Lymphoma
Researchers sought to determine the optimal dosing for venetoclax in combination with ibrutinib for patients with relapsed or refractory MCL.
Gene Expression Profiling Predicts Survival in Children With Classical Hodgkin Lymphoma
Researchers sought to develop a prognostic model for outcomes in pediatric patients with classical Hodgkin lymphoma based on gene expression data.
Yescarta Approved for Second-Line Treatment of Large B-Cell Lymphoma
The approval was based on data from the phase 3 ZUMA-7 trial.
Decision Aid Tool Helps Survivors of Lymphoma to Understand Implications of Lung Cancer Screening
Researchers sought to determine whether a decision aid tool could help survivors of Hodgkin lymphoma understand lung cancer screening.
Prognostic Model Determines Subgroups for Patients With Diffuse Large B-Cell Lymphoma
Researchers sought to develop a model to classify patients with diffuse large B-cell lymphoma into prognostic subgroups.
Bortezomib Improves EFS, OS in T-Cell Lymphoblastic Lymphoma
Bortezomib improved event-free survival and overall survival in children and young adults with T-cell lymphoblastic lymphoma.
Mosunetuzumab Induced Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas
Researchers sought to determine the dose and safety profile for mosunetuzumab administered for patients with aggressive and indolent relapsed or refractory B-NHLs.
Brentuximab Vedotin With Bendamustine Appears Safe, Effective in Pediatric Patients With Relapsed/Refractory Hodgkin Lymphoma
Researchers sought to determine whether brentuximab vedotin with bendamustine would be effective in pediatric patients with relapsed or refractory Hodgkin lymphoma.
Bone Marrow Infiltration a Risk Factor for Infusion-Related Reactions in B-Cell NHL
A retrospective study of patient data sought to determine if bone marrow infiltration is linked to adverse effect severity in patients with CD20-positive B-NHL.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...